新抗原在结直肠癌中的研究进展  

Advances in neoantigen research in colorectal cancer

作　　者：曹峥 申慧琴[2] CAO Zheng;SHEN Huiqin(The Second Clinical Medical College of Shanxi Medical University,Taiyuan,Shanxi 030000,China;Department of Gastroenterology,Second Hospital of Shanxi Medical University,Taiyuan,Shanxi 030000,China)

机构地区：[1]山西医科大学第二临床医学院,山西太原030000 [2]山西医科大学第二医院消化科,山西太原030000

出　　处：《安徽医药》2024年第9期1715-1718,共4页Anhui Medical and Pharmaceutical Journal

摘　　要：目前,结直肠癌有多种治疗策略,包括手术、化疗、放疗和靶向治疗。最新的研究发现,新抗原是一类肿瘤特异性抗原,被视为许多癌症免疫治疗的新靶点。基于新抗原的免疫治疗策略包括肿瘤疫苗和过继细胞疗法,其目的是通过增强宿主T细胞对新抗原的免疫反应来消除肿瘤细胞。该文总结了目前发现的结直肠癌新抗原及其免疫原性,并列举了基于新抗原治疗结直肠癌的临床试验,最后对当前研究面临的问题与挑战提出思考。At present,there are a variety of treatment strategies for colorectal cancer,including surgery,chemotherapy,radiotherapy and targeted therapy.Recent studies have shown that neoantigens,a class of tumor-specific antigens,are considered new targets for immunotherapy in many cancers.Neoantigen-based immunotherapeutic strategies include tumor vaccines and adoptive cell therapies,which aim to eliminate tumor cells by enhancing the immune response of host T cells to neoantigens.This paper summarizes the currently identified colorectal cancer neoantigens and their immunogenicity,lists clinical trials of neoantigen-based therapy for colorectal cancer,and concludes with reflections on the issues and challenges facing current research.

关 键 词：结直肠肿瘤 肽类 新抗原 新抗原疫苗 过继细胞疗法 临床试验 

分 类 号：R735.34[医药卫生—肿瘤]